monomethylmonothioarsonic-acid and monomethylarsonic-acid

monomethylmonothioarsonic-acid has been researched along with monomethylarsonic-acid* in 2 studies

Other Studies

2 other study(ies) available for monomethylmonothioarsonic-acid and monomethylarsonic-acid

ArticleYear
Identification of Monomethylmonothioarsonic Acid as the Major Thioarsenical Generated During Extraction Processes for Arsenic Species Analysis.
    Marine biotechnology (New York, N.Y.), 2023, Volume: 25, Issue:5

    Acid extraction is commonly used to analyze arsenic species in rice. During the extraction process, spiked monomethylarsonic acid (MMA) is often transformed into different compounds. A similar phenomenon is observed in the arsenic speciation analysis of seafood. To identify these compounds, we analyzed a previously prepared extract using liquid chromatography-time-of-flight/mass spectrometry in differential analysis and liquid chromatography-inductively coupled plasma-MS. The compound was identified as monomethylmonothioarsonic acid (MMMTA), a thioarsenical, which is estimated to be more cytotoxic than MMA. As MMMTA was readily produced by bubbling hydrogen sulfide through MMA, this suggests that MMA reacts with sulfur in rice during the extraction process. Our data also suggested that dimethylarsinic acid could be transformed into another compound, although the generation rate was low. For reliable arsenic speciation analyses, the transformation of arsenic compounds during extraction must be avoided. This study demonstrates that arsenic compounds can be transformed by dilute acid extraction.

    Topics: Arsenic; Arsenicals; Chromatography, High Pressure Liquid

2023
Arsenic speciation in saliva of acute promyelocytic leukemia patients undergoing arsenic trioxide treatment.
    Analytical and bioanalytical chemistry, 2013, Volume: 405, Issue:6

    Arsenic trioxide has been successfully used as a therapeutic in the treatment of acute promyelocytic leukemia (APL). Detailed monitoring of the therapeutic arsenic and its metabolites in various accessible specimens of APL patients can contribute to improving treatment efficacy and minimizing arsenic-induced side effects. This article focuses on the determination of arsenic species in saliva samples from APL patients undergoing arsenic treatment. Saliva samples were collected from nine APL patients over three consecutive days. The patients received 10 mg arsenic trioxide each day via intravenous infusion. The saliva samples were analyzed using high-performance liquid chromatography coupled with inductively coupled plasma mass spectrometry. Monomethylarsonous acid and monomethylmonothioarsonic acid were identified along with arsenite, dimethylarsinic acid, monomethylarsonic acid, and arsenate. Arsenite was the predominant arsenic species, accounting for 71.8 % of total arsenic in the saliva. Following the arsenic infusion each day, the percentage of methylated arsenicals significantly decreased, possibly suggesting that the arsenic methylation process was saturated by the high doses immediately after the arsenic infusion. The temporal profiles of arsenic species in saliva following each arsenic infusion over 3 days have provided information on arsenic exposure, metabolism, and excretion. These results suggest that saliva can be used as an appropriate clinical biomarker for monitoring arsenic species in APL patients.

    Topics: Adult; Antineoplastic Agents; Arsenates; Arsenic Trioxide; Arsenicals; Arsenites; Cacodylic Acid; Chromatography, High Pressure Liquid; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Leukemia, Promyelocytic, Acute; Male; Methylation; Middle Aged; Oxides; Saliva; Spectrophotometry, Atomic

2013